N
NeuroXess
Health Tech & Medtech · Minhang District, China · Founded 2021
Flexible brain-computer interface for neurological restoration MoreLess
NeuroXess is a life science company founded in 2021 by Tiger Tao and Phoenix Peng, specializing in brain-computer interface (BCI) technology. The company is focused on developing and commercializing BCI systems to assist patients with paralysis, epilepsy, and other neurological disorders. Co-founder Tiger Tao is an expert in BCI, AI, and micro-sensing, while co-founder Phoenix Peng is a serial entrepreneur, previously the founder and CEO of the SaaS company Keruyun.
NeuroXess has developed a fully implantable, wireless BCI system that uses a flexible polyimide and metal mesh that sits on the surface of the brain without penetrating the tissue. This design aims to minimize tissue damage and reduce infection risks associated with external hardware. The system includes a battery module implanted subcutaneously in the chest, enabling wireless power and data transmission. The company has achieved significant milestones, including China's first human implantation of a fully implanted BCI with an integrated battery in late 2025. Clinical trials have demonstrated the technology's ability to allow paralyzed patients to control computer cursors, play video games, and operate smart devices using their thoughts. One trial participant achieved a brain-control decoding rate of 5.2 bits per second.
The company's technology has also shown success in decoding complex language, achieving high accuracy in real-time decoding of Chinese syllables. This breakthrough has potential applications for restoring communication in patients with speech impairments. NeuroXess operates on a dual-track model where Tao leads research on cutting-edge technologies, and Peng heads the commercialization efforts. Its clients include hospitals, universities, and research centers. Having raised over $13.9 million through multiple funding rounds from investors like Shanda Capital, Sequoia Capital, and Zhongping Capital, NeuroXess plans to accelerate the commercialization of its products. The company is part of China's strategic push to become a leader in the BCI industry, supported by government initiatives and funding.
Keywords: brain-computer interface, neurotechnology, medical devices, flexible electrodes, implantable devices, paralysis treatment, neural engineering, electrocorticography (ECoG), speech decoding, motor function restoration, clinical trials, life sciences, biomaterials, neuro-prosthetics, assistive technology, human-computer interaction, Tiger Tao, Phoenix Peng, Shanghai startup, neurological disorders
Company overview
NeuroXess company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2021
- Headquarters
- Minhang District, China
- Employees
- 5
- Open positions
- None listed
- Dealroom signal
- 58.1
Valuation & funding
NeuroXess funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Dec 2022 | — | — | Shanda Group · HSG · Tianjin Wanlian Daoyi Capital · Zhongping Capital | ↗ |
| EARLY VC✓Equity / VC | Jan 2022 | $13M | $53M | HSG · New Alliance Capital · Shanda Group · Yonghua Capital | ↗ |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 5 |
Growth signals
NeuroXess website traffic
Latest recorded traffic for NeuroXess is 140 monthly website visits.
Comparisons
NeuroXess compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
NeuroXess's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where NeuroXess has talent and traffic
team presence
In the news
Latest news about NeuroXess
Recent press, funding announcements, and product moves mentioning NeuroXess — open to read from the original sources.
Market sentiment
What the market is saying about NeuroXess
An AI-synthesized read of the highest-engagement posts about NeuroXess on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NeuroXess’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.











